Details

Subject(s)

• Bioprinting [Browse]

Editor

• Katakam, Prakash [Browse]

Series

Innovations in Smart Manufacturing for Long-Term Development and Growth Series [More in this series]

Summary note

3D printing has evolved as an emerging tool for the design of customized or personalized medication that provides the maximum therapeutic benefits to patients. The manufacturing of medicines in small batches customized with tailored dosages, sizes, shapes, and drug release properties is the key prospect of using 3D printing in pharmaceutics.

Source of description

• Description based on publisher supplied metadata and other sources.
• Description based on print version record.

Contents

• Cover
• Half Title
• Series Information
• Title Page
• Copyright Page
• Table of Contents
• Preface
• About the Editors
• List of Contributors
• Section I 3D Printing, Drug Delivery Systems, and Application Domain Overview
• 1 Advancements in Tailoring Medication Using 3D Printing
• 1.1 Introduction
• 1.2 Advancements in 3DP of Patient-Specific Medical Devices
• 1.3 Dental Applications of 3DP Technology for Personalized Therapy
• 1.4 3D-Printed Drug Delivery Systems for Individualized Therapeutic Approaches
• 1.4.1 Oral Dosage Forms
• 1.4.2 Parenteral Systems
• 1.4.3 Transdermal Applications
• 1.4.4 Films
• 1.4.5 Suppositories
• 1.5 Conclusion
• References
• 2 Innovative and Modified Additive Manufacturing Processes: Extended Applications in the Pharmaceutical Industry
• 2.1 Introduction
• 2.2 Classification of Additive Manufacturing Techniques
• 2.3 3D Printing
• 2.3.1 Material Extrusion (ME) Method
• 2.3.2 Vat Polymerization
• 2.3.3 Binder Jetting
• 2.3.4 Deposition of Direct Energy
• 2.3.5 Characteristics of Different AM Processes
• 2.4 Hybrid AM Technique
• 2.5 Extended Applications in the Pharmaceutical Industry
• 2.6 Advantages of AM
• 2.7 Limitations of AM
• 2.8 Industrial Scale, Current Progress and Challenges
• 2.8.1 Industrial Scale of AM
• 2.8.2 Current Progress in AM
• 2.8.3 Challenges of AM
• 2.9 Concluding Remark
• Acknowledgments
• Section II Quality Characteristics' Challenge in 3D Printing of Pharmaceutical Products
• 3 Navigating the Terrain of 3DP for Pharmaceutical Products: Quality Conundrums and Solutions
• 3.1 Introduction
• 3.2 The Promise and Perils of 3DP in Pharmaceuticals
• 3.3 Methods of 3DP of Pharmaceutical Products
• 3.4 Quality Conundrums in 3D-Printed Pharmaceuticals
• 3.4.1 Choice of Materials and Compatibility.
• 3.4.2 Printing Specification and Accuracy
• 3.4.3 Processing Thereafter and Quality Assurance
• 3.4.4 Regulation Complying With Standards
• 3.5 Solutions to Ensure Quality in 3D-Printed Pharmaceuticals
• 3.5.1 Contemporary Material Development
• 3.5.2 Process Control and Optimisation
• 3.5.3 Monitoring in Progress and Quality Control
• 3.5.4 The Cooperation of the Industry and the Regulators
• 3.6 Conclusion
• Acknowledgements
• Section III Extrusion-Based 3D Printing in Pharmaceutics
• 4 Extrusion-Based 3D Printing in Pharmaceuticals
• 4.1 Introduction
• 4.1.1 Advantages
• 4.1.2 Limitation
• 4.2 Extrusion-Based 3D Approaches
• 4.2.1 Process of SSE Printing
• 4.2.2 Extrusion
• 4.2.3 Printing
• 4.2.4 SSE Benefits
• 4.2.5 SSE Drawback
• 4.3 3DP of Pharmaceuticals Dosage Forms Based On SSE Based 3DP: Recent Research and Applications
• 4.3.1 Immediate Release Tablets
• 4.3.2 Cancer Patches for Local Drug Delivery
• 4.4 FDM
• 4.5 3DP of Pharmaceuticals Dosage Forms Based On FDM-Based 3DP: Recent Research and Applications
• 4.5.1 Modified Released Tablets
• 4.5.2 Intermediate-Release Tablets
• 4.6 3DP of Drugs Using Extrusion: The Role of Polymer
• 4.6.1 Ethyl-Cellulose
• 4.6.2 Hydroxypropyl Cellulose (HPC)
• 4.6.3 Polycaprolactone (PCL)
• 4.6.4 Polyvinyl Alcohol (PVA)
• 4.6.5 Carbopol
• 4.7 Conclusion
• 5 Extrusion-Based 3D Printing Technology: A Revolution in Pharmaceutical Drug Manufacturing
• 5.1 Introduction
• 5.2 Fundamentals of Extrusion-Based 3D Printing (EB3D)
• 5.2.1 Fusion Deposition Modeling (FDM)
• 5.2.2 Pressure-Assisted Microsyringe (PAM)
• 5.3 Excipient and Drug Formulations
• 5.4 Pharmaceutical Applications of Extrusion-Based 3D Printing
• 5.4.1 Personalized Medicine and Dosage Forms
• 5.4.2 Novel Drug Delivery Systems.
• 5.4.3 Point-Of-Care Manufacturing and Decentralized Drug Production
• 5.5 Material Selection and Formulation Considerations
• 5.5.1 Criteria for Selecting Printable Materials
• 5.5.2 Optimization of Drug Formulation for EB3D Printing
• 5.5.3 Drug-Excipient Compatibility
• 5.5.4 Rheological Properties of Formulations
• 5.5.5 Stability and Degradation Considerations
• 5.6 Regulatory Requirements for 3D Printing Technology: Ensuring Safety, Quality, and Compliance
• 5.6.1 Quality Control and Material Characterization
• 5.6.2 Quality Assurance and Control
• 5.7 CaseStudy Reports On EB3D Printing
• 5.7.1 Case Study 1
• 5.7.2 Case Study 2
• 5.7.3 Case Study 3
• 5.8 Conclusion
• Section IV Binder Jetting-Based 3D Printing in Pharmaceutics
• 6 Binder Jetting: A Versatile and Rapid Fast 3D Printing Phenomenon
• 6.1 Introduction
• 6.2 Pharmaceutical Applications of Binding Jetting (Personalized Medicine and Dosage Forms)
• 6.2.1 Customized Drug Dosing and Formulations
• 6.2.2 Patient-Specific Implants and Medical Devices
• 6.3 Novel Drug Delivery Systems
• 6.3.1 Sustained Release Formulations
• 6.3.2 Multi-Drug Combination Products
• 6.4 Process Parameters and Optimization for Pharmaceutical Application
• 6.4.1 Rheological Properties and Flow Behavior of Pharmaceutical Binders
• 6.4.2 Binder Penetration and Bonding Strength Optimization for Drug Delivery Systems
• 6.4.3 Print Parameters' Optimization
• 6.5 Quality Control and Characterization of Binder Jetted Pharmaceutical Products
• 6.5.1 Mechanical Testing and Material Characterization
• 6.5.2 Drug-Excipient Compatibility and Stability Studies
• 6.5.3 Dissolution and Drug-Release Testing
• 6.5.4 In Vitro and In Vivo Performance Assessment
• 6.6 Case Studies and Examples
• 6.6.1 Case Study 1: BJ of Customized Oral Dosage Forms.
• 6.6.2 Case Study 2: Patient-Specific Implants and Medical Devices
• 6.6.3 Case Study 3: BJ for Controlled-Release Drug Delivery Systems
• 6.7 Regulatory Considerations and Challenges
• 6.8 Intellectual Property and Patent Issues in Pharmaceutical 3D Printing
• 6.8.1 Advancements in BJ Technology for Pharmaceutical Applications
• 6.8.2 Integration of BJ With Other 3D Printing Techniques
• 6.9 Potential Impact On Personalized Medicine and Patient Care
• 6.10 Conclusion
• 7 Binder Jetting-Based 3D Printing in Pharmaceutics
• 7.1 Introduction
• 7.2 Components of BJP
• 7.2.1 Powder Mixture
• 7.2.1.1 Powder-Specific Properties
• 7.2.1.2 Powder-binding Interaction
• 7.2.2 Binder Solution
• 7.3 Method of Preparation
• 7.3.1 Critical Raw Materials
• 7.3.2 Critical Process Parameter
• 7.4 Benefit
• 7.5 Drawbacks/Challenges
• 7.6 Application of BJP in Pharmaceutical Manufacturing
• 7.6.1 Drugs in Ink Method
• 7.6.2 Drugs in Powder Method
• 7.7 Conclusion and Future Perspective
• Section V SLS and SLA-Based 3D Printing in Pharmaceutics
• 8 SLS and SLA Techniques in 3D Printing for Better Pharmaceutical Applicability of Soft Materials
• 8.1 Introduction
• 8.1.1 Importance of Soft Materials in 3DP
• 8.1.2 Significance of SLS and SLA Techniques in Pharmaceuticals
• 8.2 Purpose and Scope of The Chapter
• 8.3 Fundamentals of SLS and SLA Techniques
• 8.4 Explanation of SLS Technique
• 8.5 Explanation of SLA Technique
• 8.6 Soft Materials in Pharmaceutical Application
• 8.6.1 Developing Personalized Medicine, Controlled and Sustained Release Formulations Using Soft Materials
• 8.6.2 Soft Materials Applications With 3DP in Generating Tissue Scaffolds
• 8.7 Optimization of SLS and SLA Parameters for Soft Material
• 8.8 Case Studies and Examples of SLS AND SLA Printing.
• 8.9 Future Perspectives and Challenges
• 8.9.1 Challenges and Limitations
• 8.9.2 Post-Processing
• 8.9.3 Material Limitations
• 8.9.4 Size Constraints
• 8.10 Regulatory Considerations for 3DP Soft Materials in Pharmaceuticals
• 8.11 Conclusion
• Section VI Hybrid 3D Printing Techniques in Pharmaceutical Applications
• 9 Next-Generation Computational Automation-Based Additive Manufacturing of Pharmaceuticals: An Approach to Fabricate Precise Medicine
• 9.1 Introduction
• 9.2 Processes for 3D Printing
• 9.3 Computational Automation Involved Computer-Aided Designs and AI-Based Software in 3D Printing
• 9.4 Materials Used in the 3D Printing Process
• 9.5 Material Requirements for Preparation of Bioprinting Ink
• 9.5.1 Natural Bioinks
• 9.5.2 Synthetic Bioinks
• 9.6 Challenges and Opportunities in Bioink
• 9.7 Bio-Medical Application of 3D Printing
• 9.7.1 Application of 3D Printing in Fabricating Pharmaceuticals
• 9.7.2 Application of 3D Printing in Biodegradable Biomedicals
• 9.7.3 Application of 3D Printing in Tissue and Bone Engineering
• 9.8 Conclusions
• Section VII Social, Economic, Environmental, Quality, and Regulatory Aspects
• 10 Social, Economic, and Environmental Justifications for 3D Printing of Pharmaceutical Products
• 10.1 Introduction
• 10.2 Precise Dosage and Formulations
• 10.2.1 Tailored Medications for Specific Conditions
• 10.2.2 Potential for Patient Empowerment and Engagement in Healthcare
• 10.2.3 Personalization Treatments
• 10.2.4 Informed Decision-Making
• 10.3 Ethical Challenges Associated With the 3D Printing of Pharmaceutical Products
• 10.3.1 Quality Control
• 10.3.2 Intellectual Property Issues
• 10.3.3 Regulatory Frameworks
• 10.3.4 Accessibility and Equity
• 10.4 Factors IMPACTING THE Cost-Effectiveness of 3D Printing.
• 10.5 Cost-Effectiveness of 3D Printing in the Pharmaceutical Industry, Considering Factors Like Distribution Costs.

Show 199 more Contents items

ISBN

• 1-003-43950-0
• 1-04-022458-X

Statement on language in description

Princeton University Library aims to describe library materials in a manner that is respectful to the individuals and communities who create, use, and are represented in the collections we manage. Read more...